Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor...

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Inhibiting vascular endothelial growth factor receptor-2 (VEGFR2) is a validated cancer therapeutic strategy.
• Existing small molecule VEGFR2 inhibitors often lack selectivity, leading to adverse effects and limited efficacy.
• There is a need for more potent and selective VEGFR2 inhibitors.

Purpose of the Study:

• To characterize the pharmacological properties of anlotinib, a novel VEGFR2 inhibitor.
• To evaluate the preclinical antitumor efficacy of anlotinib in various cancer models.
• To compare anlotinib's efficacy with sunitinib, a known tyrosine kinase inhibitor.

Main Methods:

• In vitro biochemical assays to determine VEGFR2 inhibitory potency and selectivity.
• Cell-based assays using human umbilical vein endothelial cells (HUVECs) to assess anti-angiogenic effects.
• In vivo studies in nude mice to evaluate anlotinib's antitumor efficacy and tolerability.

Main Results:

• Anlotinib demonstrated high potency and selectivity for VEGFR2, with IC50 values in the low nanomolar range.
• Anlotinib effectively inhibited VEGF-induced signaling, HUVEC proliferation, migration, and tube formation.
• In vivo, anlotinib exhibited superior antitumor efficacy compared to sunitinib, including tumor regression in some models.

Conclusions:

• Anlotinib is a potent, selective, and orally active VEGFR2 inhibitor with significant preclinical antitumor activity.
• Anlotinib effectively targets tumor angiogenesis and demonstrates promising efficacy in preclinical cancer models.
• Anlotinib's favorable pharmacological profile supports its ongoing clinical evaluation for various malignancies.